DVA (74) SHC (49) PGNY (79) AGL (36) ⌘ Pro Terminal →

Fresenius Medical Care AG American (FMS) — RQD Stock Rating Cockpit

$22.47 -2.85% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.31

Fresenius Medical Care AG American (FMS) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $12.55B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FMS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Fresenius Medical Care AG American (NYSE: FMS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $22.47 (-2.85% 1D, market cap $12.55B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, FMS ranks #187 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FMS compare to DVA and SHC in the Health Care sector?

▼

Within the Health Care sector (Misc Health and Biotechnology Services), FMS carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, DVA (DaVita Inc.) holds a B grade (74/100 RQD, P/E 11.4x, ROIC 29.2%, cap $11.79B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FMS?

▼

For Fresenius Medical Care AG American (FMS), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #187 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $22.31 (-0.70%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 6.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FMS)Realized 20D OHLCV Swing Band: ±4.4%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY FMS SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (21% of score)

SEC XBRL Trailing 12 Months: 6.9% FCF Margin ($277.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$21.54+0.1% Next Q

Q2 (-2Q)

Grade C-$21.56+4.9% Next Q

Q3 (-1Q)

Grade C-$22.62-0.7% Next Q

Current

Grade D+$22.47-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the FMS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, FMS faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($22.35) or 200D SMA ($22.89) invalidates the momentum regime and cuts Target Base ($22.37) toward Bear Floor ($17.45).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FMS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.74>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE38% OF RANGE

L: $20$22.47H: $26

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on FMS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

9.9% ROIC with 42.0% gross margin and 2.21% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 3.74 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (48)

20/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like FMS

✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FMS)

✓Walkthrough of FMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.79%▼ DESCENDING CHANNEL

2026-11-03O $23.13H $23.13L $22.47C $22.47VOL 968.0K

RES: $23.11SUP: $19.65SMA50: $22.35SMA200: $22.89

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FMS Butterfly Map → + Track FMS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. -3.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FMS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FMS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FMS)

Health Care Rank #187 of 1016 ⚔️ DVA vs FMS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FMS vs. DVA, SHC, PGNY, AGL)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Fresenius Medical Care AG American (FMS) ranks #187 by composite RQD confidence (57/100, grade D+) and #90 by equity capitalization ($12.55B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with FMS at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FMS ACTIVE Fresenius Medical Care AG American	D+	57/100	32.8x	—	9.9%	-2.85%	$12.55B	Benchmark Subject
DVA DaVita Inc.	B	74/100	11.4x	—	29.2%	-3.01%	$11.79B	/dva-vs-fms →
SHC Sotera Health Company	D	49/100	68.5x	55.5%	3.1%	-2.94%	$5.18B	/shc-vs-fms →
PGNY Progyny Inc.	B+	79/100	37.2x	23.6%	16.7%	+2.78%	$2.24B	/pgny-vs-fms →
AGL agilon health inc.	D-	36/100	—	—	-35.0%	-1.21%	$1.43B	/agl-vs-fms →

2. FMS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Fresenius Medical Care AG American (FMS) operates in Misc Health and Biotechnology Services (Health Care) with an equity capitalization of $12.55B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 7/9.

3. FMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does FMS compare to DVA and SHC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for FMS?

Where is FMS trading relative to its 50-day, 200-day, and 52-week technical levels?

FMS last traded at $22.47 (-2.85% on volume of 967,987 shares), positioning the stock +0.54% above its 50-day simple moving average ($22.35) and -1.83% below its 200-day simple moving average ($22.89). Across its 52-week range of $20.02 to $26.42, FMS sits at the 38.3% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±4.4% ($21.48 to $23.46).

FMS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell FMS stock right now?

Fresenius Medical Care AG American (FMS) currently earns a Roarable Rating of D+ (Sell — SELL) with 57/100 RQD Confidence. Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.

What is FMS's 12-month price target and RQD AI Jury consensus?

FMS's 12-month base price target is $22.37 (range $17.45 to $27.74), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: FMS RQD Cockpit FMS 12M Forecast FMS Earnings & Move FMS Dividends & DRIP FMS Insiders & 13F FMS Whale Options FMS Profit Sankey FMS News & Why

ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

FMS — Fresenius Medical Care AG American: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:10:07Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, FMS scores 64 out of 100, a letter grade of C, and the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, ROIC is 9.9% and FCF yield is 2.21%. Returns on invested capital are positive but modest, and the free cash flow yield is thin relative to the share price, which leaves limited cash cushion for valuation support.
Whale 13F Flow: 11 / 20. The pillar reflects institutional accumulation and options positioning. The underlying 13F and options detail is not provided in the source data, so the score cannot be decomposed further.
Insider Conviction: 12 / 20. The pillar reflects SEC Form 4 and Congressional PTR cluster flow. The underlying transaction detail is not provided in the source data.
Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 0.9, indicating below-market sensitivity to broad market moves. The sector sensitivity detail behind the score is not provided in the source data.
Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, the Altman Z-Score is 3.74, the Piotroski F-Score is 7/9, and Debt/Equity is 0.39. This is the strongest pillar and points to a financially sound balance sheet.

For a prospective investor, the rating describes a stock whose balance sheet is its clearest strength, while cash generation, institutional and insider signals, and macro fit are only moderate. The upside case depends on converting operating earnings into stronger free cash flow. Valuation is a central tradeoff: per the market data, P/E (TTM) is 32.8 and Forward P/E is 30.5, against an FCF yield of 2.21%. The rating's Hold verdict reflects this balance of solid financial footing against a demanding valuation and modest cash returns.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
$23.13	$12.92B	32.8	30.5	21	0.7	0%	0.9	$20.02 - $26.66	9.9%

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data.

Open Questions

What are the reported revenue, operating income, net income, free cash flow, cash, and debt across recent periods? The financial statements are absent, so the trend cannot be verified.
What is driving the 0% gross margin figure, and is it a data artifact or a reporting feature?
What products and customers generate revenue, and how concentrated is that revenue?
What are the 13F holder changes, options positioning, and insider transactions behind the Whale and Insider pillar scores?
What recent catalysts or risks explain the stock's position within its $20.02 - $26.66 52-week range?

FMS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Fresenius Medical Care AG American (FMS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FMS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 10d ago

FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI

Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12d ago

Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney Injury

Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous

Read Full Source ↗

🔴 RISK WATCH Yahoo • 12d ago

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney i

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 13d ago

'HHS releases new kidney care plan' - Axios Exclusive

https://www.axios.com/2026/10/20/kidney-care-plan-kennedy

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 14d ago

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the Ame

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 26d ago

Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced that Shervin J. Korangy (51) will become Chief Executive Officer (CEO) and Chair of

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 34d ago

Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth

FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 38d ago

Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

Yahoo Finance coverage on FMS stock catalysts, institutional flow, and earnings outlook.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FMS Bull vs. Bear Conversation Board — What's Your Call at $22.47?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FMS 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $24.98 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is FMS (C • RQD 64/100) a Buy at $23.13?

Welcome to the FMS (Fresenius Medical Care AG American) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Misc Health and Biotechnology Services. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $18.27 (-21.0%)

Spot @ $23.13

Pump the brakes on FMS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on FMS, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Fresenius Medical Care AG American expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $26.37 (+14.0%)

Spot @ $23.13

FMS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on FMS, the market is fixating on short-term headline noise in Misc Health and Biotechnology Services and ignoring the balance sheet and cash flow trajectory. At $23.13 (52-wk range $20.02 - $26.66), any beat on forward guidance forces shorts and underweight funds to chase.